CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
Barbara Savoldo, Carlos Almeida Ramos, Enli Liu et al. · Journal of Clinical Investigation · 2011
Targeted T cell immunotherapies using engineered T lymphocytes expressing tumor-directed chimeric antigen receptors (CARs) are designed to benefit patients with cancer. Although incorporation of costimulatory endodomains within these CARs increases the proliferation of CAR-redirected T lymphocytes, it has proven difficult to draw definitive conclusions about the specific effects of costimulatory endodomains on the expansion, persistence, and antitumor effectiveness of CAR-redirected T cells in human subjects, owing to the lack of side-by-side comparisons with T cells bearing only a single signaling domain. We therefore designed a study that allowed us to directly measure the consequences of adding a costimulatory endodomain to CAR-redirected T cells. Patients with B cell lymphomas were simultaneously infused with 2 autologous T cell products expressing CARs with the same specificity for the CD19 antigen, present on most B cell malignancies. One CAR encoded both the costimulatory CD28 and the ζ-endodomains, while the other encoded only the ζ-endodomain. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced expansion and persistence compared with CAR+ T cells lacking this endodomain. These results demonstrate the superiority of CARs with dual signal domains and confirm a method of comparing CAR-modified T cells within individual patients, thereby avoiding patient-to-patient variability and accelerating the development of optimal T cell immunotherapies.
Cited by 1,021 works. doi:10.1172/jci46110
Authors
- Barbara Savoldo
- Enli Liu
- Martha Pritchett Mims
- Michael J. Keating
- George Carrum
- Rammurti T. Kamble
- Catherine M. Bollard
- Adrian P. Gee
- Zhuyong Mei
- Hao Liu
- Bambi Grilley
- Cliona M. Rooney
- Helen Elisabeth Heslop
- Malcolm K. Brenner
- Gianpietro Dotti
References
- Revised Response Criteria for Malignant Lymphoma
- NF-κB at the crossroads of life and death
- The B7–CD28 superfamily
- Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
- Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
- Immunosuppressive networks in the tumour environment and their therapeutic relevance
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
- Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
- A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer